Semax in the HHS Draft: Intranasal Free Base, Not Every Formulation

HHS included Semax in a six-substance draft interim enforcement-discretion policy. The Federal Register notice explicitly identifies it as a draft and says it is not binding on HHS or the public. Scheduled Federal Register publication is October 30, 2026, with comments accepted for two weeks after publication. The announcement should not be described as final FDA approval or automatic availability.

The draft addresses compounding while FDA develops the 503A bulk-substances list through rulemaking. It does not establish an approved indication for memory, attention, neurological recovery, or another condition. The policy overview explains the six-substance list without treating advisory or policy decisions as clinical efficacy findings.

Appendix B specifies Semax free base for intranasal use. Its identity entry gives the seven-amino-acid sequence Met-Glu-His-Phe-Pro-Gly-Pro. The HHS document’s route and identity requirements mean that “Semax” on a label is not enough to establish that a preparation matches the draft.

Semax acetate and injectable Semax should not be represented as covered by this free-base intranasal entry. That distinction can be easy to miss because the rationale discusses analytical results relevant to injectable use and says the advisory committee favored both forms it considered. The final route statement within the draft remains intranasal free base; background discussion does not expand that statement.

HHS describes an intranasal human record covering several hundred subjects with no reported adverse outcome, drawing on material CDER had compiled. It also says the bleeding and abuse-potential concerns raised in the earlier assessment lacked a clinical counterpart in that record. These are HHS’s characterizations of the evidence used in a policy decision.

They should not be rewritten as proof that Semax improves cognition in healthy people or treats every neurological diagnosis. Safety observations and efficacy outcomes answer different questions. A study population with one condition may also differ substantially from a person seeking better focus at work. The exact preparation, clinical setting, outcome measures, and follow-up period matter.

FDA’s July 2026 briefing found insufficient efficacy evidence for cerebral ischemia, migraine, and trigeminal neuralgia. It also distinguished one reference reporting no adverse events from others that did not discuss adverse events. Missing reporting is not the same as actively demonstrating that no events occurred. The same briefing also records a consumer FAERS report of eye pain, burning, and hospitalization after intranasal Semax drops purchased online. An adverse-event report does not establish causation or an event rate, but it should not disappear from the safety discussion. These limitations help readers interpret HHS’s later description of the human exposure record. FDA Semax briefing

The FDA’s April 22, 2026 safety page describes potential immunogenicity related to aggregation and peptide impurities, alongside limited safety-related information for proposed routes. The page predates the October draft. Its historical assessment and HHS’s later interpretation should both be dated, rather than presented as if they were one simultaneous conclusion.

Several hundred exposed participants can provide useful information without resolving rare reactions, long-term use, interactions, or every patient subgroup. “No reported adverse outcome” also depends on how events were sought and reported. It does not justify a risk-free label. The draft’s single-API and reporting conditions are intended to support clearer attribution if safety signals emerge.

HHS describes additional certificates reporting identity, purity, quantified impurities, residual solvents, and endotoxin information. The broader policy requires original-manufacturer FDA registration, CGMP compliance, appropriate certificates of analysis, and matching chemical identity. These checks help address what is in a preparation and where it came from.

They do not establish cognitive benefit or replace a clinician’s assessment. The draft separately requires a patient-specific prescription, labeling identifying the product as compounded and not for resale, and reporting of serious adverse events and quality problems. The draft allows only an FDA 510(k)-cleared syringe as a co-packaged or drug-containing delivery device. Its intranasal route statement does not waive that separate condition or establish that a nasal spray device qualifies; a pharmacist must resolve the specific product and device requirements.

Begin by naming the problem: persistent attention difficulties, memory changes, and recovery after a neurological illness call for different evaluations. Ask what established care options fit the diagnosis and what evidence supports the exact proposed Semax preparation. New or worsening neurological symptoms should not be treated as a reason to self-select a peptide from a search result.

If compounding is discussed, ask about the free-base identity, intranasal formulation, current policy status, dispensing pharmacy, and follow-up plan. Do not infer a dose, device choice, or administration protocol from this article. The draft does not guarantee a prescription or availability through Peppy. It is an evolving regulatory document, not a personalized treatment recommendation.